The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis Publisher Pubmed



Gorabi AM¹ ; Kiaie N¹ ; Reiner Z² ; Carbone F^{3, 4, 5} ; Montecucco F^{3, 4, 5, 6} ; Sahebkar A^{7, 8, 9} Show Affiliations
Source: Biomolecules Published:2019

Abstract

Chronic inflammation is one of the main determinants of atherogenesis. The traditional medications for treatment of atherosclerosis are not very efficient in targeting atherosclerotic inflammation. Most of these drugs are non-selective, anti-inflammatory and immunosuppressive agents that have adverse effects and very limited anti-atherosclerotic effects, which limits their systemic administration. New approaches using nanoparticles have been investigated to specifically deliver therapeutic agents directly on atherosclerotic lesions. The use of drug delivery systems, such as polymeric nanoparticles, liposomes, and carbon nanotubes are attractive strategies, but some limitations exist. For instance, nanoparticles may alter the drug kinetics, based on the pathophysiological mechanisms of the diseases. In this review, we will update pathophysiological evidence for the use of nanoparticles to reduce inflammation and potentially prevent atherogenesis in different experimental models. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.